Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Completed · Phase 1

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cladribine when given with bryostatin 1 in treating patients with relapsed chronic lymphocytic leukemia.

Key facts

Study ID

NCT00003174

Run by

Barbara Ann Karmanos Cancer Institute

People needed

80

Starts

1998-05-01

Expected to finish

2005-11-01

Last updated by the study team

2014-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
• Van Elslander Cancer Center at St. John Hospital and Medical Center — Grosse Pointe Woods, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.